Literature DB >> 27371543

[Anesthesiological approach for patients with spinal cord injuries].

A Rand1, R J Litz2, P Zahn2.   

Abstract

Spinal cord injuries (SCI) are serious medical conditions, which are associated with severe and potentially fatal risks and complications depending on the location and extent of injury. Traffic accidents, falls and recreational activities are the leading causes for traumatic SCI (TSCI) worldwide whereas non-traumatic spinal cord injuries (NTSCI) are mostly due to tumors and congenital diseases. As chronification of the injuries progresses other organ systems are affected including anatomical changes, the respiratory and cardiovascular systems and endocrinological pathways. All these effects have to be considered in the anesthesiological management of patients with SCI. Autonomic dysreflexia (AD) is the most dangerous and life-threatening complication in patients with chronic SCI above T6 that results from an overstimulation of sympathetic reflex circuits in the upper thoracic spine and can be fatal. This article summarizes the specific pathophysiology of SCI and how AD can be avoided as well as also providing anesthetists with strategies for perioperative and intensive care management of patients with SCI.

Entities:  

Keywords:  Autonomic dysreflexia; Autonomic nervous system; Paralysis; Shock; Trauma

Mesh:

Year:  2016        PMID: 27371543     DOI: 10.1007/s00101-016-0193-0

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  76 in total

1.  Recurrent autonomic dysreflexia exacerbates vascular dysfunction after spinal cord injury.

Authors:  Nima Alan; Leanne M Ramer; Jessica A Inskip; Saeid Golbidi; Matt S Ramer; Ismail Laher; Andrei V Krassioukov
Journal:  Spine J       Date:  2010-12       Impact factor: 4.166

Review 2.  Epidemiology, demographics, and pathophysiology of acute spinal cord injury.

Authors:  L H Sekhon; M G Fehlings
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

Review 3.  Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury.

Authors:  Alexander G Rabchevsky; Patrick H Kitzman
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 4.  Acute complications of spinal cord injuries.

Authors:  Ellen Merete Hagen
Journal:  World J Orthop       Date:  2015-01-18

5.  Epidural meperidine for control of autonomic hyperreflexia in a paraplegic parturient.

Authors:  A Baraka
Journal:  Anesthesiology       Date:  1985-05       Impact factor: 7.892

Review 6.  Epidemiology of traumatic spinal cord injury in developing countries: a systematic review.

Authors:  Vafa Rahimi-Movaghar; Mohammad Kazem Sayyah; Hesam Akbari; Reza Khorramirouz; Mohammad R Rasouli; Maziar Moradi-Lakeh; Farhad Shokraneh; Alexander R Vaccaro
Journal:  Neuroepidemiology       Date:  2013-06-13       Impact factor: 3.282

7.  Sevoflurane concentrations required to block autonomic hyperreflexia during transurethral litholapaxy in patients with complete spinal cord injury.

Authors:  Kyung Y Yoo; Cheol W Jeong; Seok J Kim; Sung T Chung; Hong B Bae; Kyung J Oh; Jongun Lee
Journal:  Anesthesiology       Date:  2008-05       Impact factor: 7.892

8.  Open-heart operations in patients with a spinal cord injury.

Authors:  Danny Chu; Faisal G Bakaeen; Salwa A Shenaq; Miran Ribati; Prasad V Atluri; Sally A Holmes; David H Berger; Joseph Huh
Journal:  Am J Surg       Date:  2007-11       Impact factor: 2.565

9.  Clinical trial of a method for confirming the effects of spinal anesthesia in patients with spinal cord injury.

Authors:  Akiko Takatsuki; Masahide Ohtsuka
Journal:  J Anesth       Date:  2012-06-19       Impact factor: 2.078

10.  Severe autonomic dysreflexia induced cardiac arrest under isoflurane anesthesia in a patient with lower thoracic spine injury.

Authors:  Amit Jain; Babita Ghai; Kajal Jain; Jeetinder K Makkar; Kishore Mangal; Supriya Sampley
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.